AQR Capital Management LLC Cuts Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX)

AQR Capital Management LLC trimmed its position in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 47.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 288,499 shares of the company's stock after selling 257,709 shares during the quarter. AQR Capital Management LLC owned 0.62% of Pacira BioSciences worth $5,435,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PCRX. Northern Trust Corp increased its stake in shares of Pacira BioSciences by 30.8% in the 4th quarter. Northern Trust Corp now owns 616,891 shares of the company's stock valued at $11,622,000 after acquiring an additional 145,205 shares during the last quarter. Tudor Investment Corp ET AL bought a new stake in Pacira BioSciences in the fourth quarter valued at approximately $427,000. State of Tennessee Department of Treasury grew its stake in shares of Pacira BioSciences by 14.2% in the fourth quarter. State of Tennessee Department of Treasury now owns 26,180 shares of the company's stock valued at $493,000 after acquiring an additional 3,264 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of Pacira BioSciences by 5.6% during the 4th quarter. MetLife Investment Management LLC now owns 27,883 shares of the company's stock worth $525,000 after acquiring an additional 1,471 shares during the period. Finally, Natixis acquired a new position in Pacira BioSciences during the 4th quarter worth approximately $1,738,000. Institutional investors and hedge funds own 99.73% of the company's stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on PCRX. Needham & Company LLC lowered their price objective on Pacira BioSciences from $32.00 to $30.00 and set a "buy" rating for the company in a research report on Friday. Truist Financial raised Pacira BioSciences from a "sell" rating to a "hold" rating and lifted their price objective for the stock from $8.00 to $25.00 in a report on Thursday, January 30th. HC Wainwright increased their target price on shares of Pacira BioSciences from $48.00 to $65.00 and gave the stock a "buy" rating in a research note on Tuesday, April 8th. Barclays upped their price objective on Pacira BioSciences from $17.00 to $24.00 and gave the stock an "overweight" rating in a report on Friday, February 28th. Finally, Royal Bank of Canada reissued a "sector perform" rating and set a $18.00 price objective on shares of Pacira BioSciences in a research note on Tuesday, January 14th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $26.44.

Pacira BioSciences Trading Up 0.8 %

NASDAQ PCRX traded up $0.21 on Friday, reaching $25.12. 2,242,337 shares of the company were exchanged, compared to its average volume of 963,506. Pacira BioSciences, Inc. has a fifty-two week low of $11.16 and a fifty-two week high of $31.67. The stock has a market capitalization of $1.16 billion, a P/E ratio of -12.37 and a beta of 0.56. The business's fifty day moving average price is $24.73 and its 200 day moving average price is $22.13. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Company Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients' journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.